Clinical Trial Update: Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer [Phase 4]

View source ↗

Summary

A phase 4 clinical trial update evaluating a PCSK9 inhibitor in patients at very high risk of ASCVD and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Xiang Xie | Conditions: ASCVD, Atherosclerotic Cardiovascular Disease | Phase 4 | Status: UNKNOWN